US 11,746,090 B2
Crystal forms of 2-[4-[(2,3,4- trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
Neil Buckley, Boston, MA (US); Dan Belmont, Boston, MA (US); Sarah Bethune, Boston, MA (US); and Krista Diaz, Boston, MA (US)
Assigned to IMBRIA PHARMACEUTICALS, INC., Boston, MA (US)
Filed by IMBRIA PHARMACEUTICALS, INC., Boston, MA (US)
Filed on Nov. 14, 2022, as Appl. No. 17/986,419.
Application 17/986,419 is a continuation of application No. 17/359,736, filed on Jun. 28, 2021, granted, now 11,530,184.
Claims priority of provisional application 63/046,120, filed on Jun. 30, 2020.
Prior Publication US 2023/0093615 A1, Mar. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 213/80 (2006.01)
CPC C07D 213/80 (2013.01) [C07B 2200/13 (2013.01)] 25 Claims
 
1. A crystal comprising a Form A polymorph of a compound of Formula (X):

OG Complex Work Unit Chemistry
wherein the Form A polymorph has an endothermic peak at about 85.3° C. (±5° C.) and at about 214.6° C. (±5° C.) in a differential scanning calorimetry (DSC) thermogram.